List of Excipients in Branded Drug VERDESO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	VERDESO	desonide	16110-111	ANHYDROUS CITRIC ACID
Almirall LLC	VERDESO	desonide	16110-111	CETYL ALCOHOL
Almirall LLC	VERDESO	desonide	16110-111	CYCLOMETHICONE
Almirall LLC	VERDESO	desonide	16110-111	ISOPROPYL MYRISTATE
Almirall LLC	VERDESO	desonide	16110-111	LIGHT MINERAL OIL

Verdeso Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Verdeso is a prescription topical foam containing desonide 0.05%, a low-potency corticosteroid for mild to moderate atopic dermatitis in patients aged 3 months and older. Its commercial value is tied less to the active pharmaceutical ingredient, which is established and widely available, than to aerosol-foam performance, pediatric tolerability, skin feel, preservation, packaging, and regulatory substitutability.[1]

The strongest opportunities are generic or authorized-generic foam development, improved pediatric and sensitive-skin formulations, and delivery systems that preserve rapid application without relying on the original aerosol architecture.

What is Verdeso and how does its formulation work?

Verdeso is a topical aerosol foam. Its active ingredient is desonide at a concentration of 0.05%.[1]

The FDA-approved formulation contains the following inactive ingredients:

Excipient or component	Likely formulation role
Cetyl alcohol	Emollient, consistency agent and foam-structure support
Stearyl alcohol	Emollient and viscosity modifier
Polysorbate 60	Surfactant and emulsification aid
Propylene glycol	Humectant, solvent and skin-penetration aid
Methylparaben	Preservative
Edetate disodium	Chelating agent that supports preservative performance
Citric acid	pH adjustment
Potassium citrate	Buffering system
Purified water	Continuous aqueous phase
Isobutane	Aerosol propellant

The formulation is designed to spread over affected skin as a light foam that collapses during application. This can reduce the occlusive and greasy feel associated with ointments while improving coverage over hair-bearing or inflamed areas.

Why the excipient system matters

The main technical challenge is balancing four variables:

1. Foam generation and collapse.
2. Desonide solubilization or uniform dispersion.
3. Skin tolerability, particularly in infants and patients with barrier-impaired skin.
4. Container and valve compatibility over shelf life.

Cetyl alcohol and stearyl alcohol create a fatty alcohol matrix that contributes to consistency and emolliency. Polysorbate 60 supports dispersion and interfacial stability. Propylene glycol can improve wetting and application but may cause irritation or stinging in some patients with compromised skin. Methylparaben provides preservation, while edetate disodium strengthens preservative performance by binding trace metals.

Isobutane is commercially important because it creates a conventional aerosol foam but introduces flammability, pressure, packaging and transportation constraints.

What excipient strategy is optimal for a Verdeso generic?

A generic developer should initially pursue a close formulation match rather than a visibly differentiated excipient system. The first commercial objective is an ANDA with pharmaceutical equivalence, bioequivalence and comparable product performance under FDA requirements.[2]

Base-case formulation strategy

The lowest regulatory-risk approach is to retain the core architecture:

• Water-based emulsion or suspension system.
• Fatty alcohol structure using cetyl alcohol, stearyl alcohol or an equivalent combination.
• Nonionic surfactant.
• Propylene glycol or another established humectant.
• Preservative system.
• Buffer near the reference product’s pH.
• Hydrocarbon propellant or an equivalent aerosol system.
• Compatible aluminum or coated aerosol container with metered or controlled dispensing.

A close formulation can reduce development risk in rheology, foam density, collapse time, delivered dose and skin distribution. The tradeoff is limited differentiation and potential price competition.

Differentiated excipient strategies

A second-generation product could target one or more of the following:

Strategy	Commercial benefit	Main development issue
Preservative-free formulation	Appeals to sensitive-skin and pediatric users	Requires validated microbial control and container-closure protection
Lower-propylene-glycol formulation	May reduce stinging or irritation	May affect solubility, viscosity and skin delivery
HFA or alternative propellant	Could reduce hydrocarbon-flammability concerns	Requires new container, pressure and performance studies
Bag-on-valve foam	May improve product isolation and dispensing consistency	Higher packaging cost and different device regulatory burden
Pump or mechanical foam	Avoids compressed propellant	Dose uniformity and foam quality may differ
Reduced-residue emulsion	Improves cosmetic acceptability	May alter residence time and clinical performance
Enhanced emollient system	Supports barrier-compromised skin	Can create greasiness or affect corticosteroid release
Single-use or unit-dose packaging	Supports pediatric and travel use	Higher manufacturing and packaging expense

The most commercially credible improvement is a low-irritancy, preservative-reduced or preservative-free foam with a controlled-dispensing package. A full propellant redesign has greater differentiation potential but also carries a higher regulatory and technical burden.

Which excipients create the greatest intellectual-property and regulatory risk?

The active ingredient desonide is a mature small molecule. Competitive protection is therefore more likely to arise from formulation, aerosol delivery, container-closure design, manufacturing controls or method-of-use claims than from the molecule itself.

Formulation patent risk

Potentially relevant claim categories include:

• Specific ratios of fatty alcohols and surfactants.
• Foamable compositions containing corticosteroids.
• Propellant systems and pressure ranges.
• Aerosol valve and actuator configurations.
• Particle-size or droplet-size controls.
• Non-greasy topical corticosteroid vehicles.
• Preservative systems for water-containing aerosol foams.
• Manufacturing processes that control drug distribution or foam collapse.

A generic sponsor must review current FDA Orange Book listings for the reference product, relevant patent-family records and any active regulatory exclusivity.[3] Patent status cannot be inferred solely from the product label or from historical patent publications.

Paragraph IV exposure

Because Verdeso is a small-molecule drug, an ANDA applicant could face Paragraph IV litigation if the reference product has eligible listed patents. The litigation risk depends on the specific patents listed at the time of ANDA filing, the proposed label, and whether the applicant certifies invalidity, unenforceability or non-infringement.[2]

A design-around strategy could focus on:

• A non-infringing excipient ratio.
• A different propellant or non-aerosol delivery system.
• A mechanical foam package.
• A distinct preservative architecture.
• A method-of-use carve-out for protected indications or patient groups.

A formulation change that improves consumer appeal but creates a new dosage form or device may require a 505(b)(2) pathway rather than a conventional ANDA. That route can support differentiation but usually increases clinical, regulatory and commercial cost.

What is the FDA regulatory status of Verdeso?

Verdeso was approved by FDA as a new drug application for topical desonide foam.[1] The approved indication covers mild to moderate atopic dermatitis in patients 3 months of age and older.

The label includes class-related warnings for topical corticosteroids, including the potential for hypothalamic-pituitary-adrenal axis suppression, particularly with extensive application, prolonged use, occlusion or use in susceptible patients.[1]

The pediatric population is commercially important. Infants and young children have a higher need for low-potency corticosteroids, but excipient tolerability and dosing control are critical. A product that produces excessive stinging, residue or inconsistent discharge may lose adoption even if it meets formal pharmaceutical-equivalence requirements.

Regulatory pathway comparison

Product concept	Likely pathway	Commercial implication
Close desonide 0.05% aerosol foam	ANDA, subject to FDA requirements	Fastest route to price competition
Same strength with meaningful excipient change	ANDA if equivalence can be established	Moderate development risk
Preservative-free or alternative-vehicle foam	ANDA or 505(b)(2), depending on differences	Higher differentiation potential
New device or mechanical foam	Often 505(b)(2) or combination-product analysis	Greater device and performance burden
New concentration or expanded indication	505(b)(2) or NDA supplement strategy	Requires broader clinical and regulatory support
Desonide biosimilar	Not applicable	Desonide is a small molecule, not a biologic

There is no biosimilar pathway for Verdeso. Competition will come from generic topical corticosteroids, branded reformulations and other non-biologic dermatology products.

What commercial opportunities exist for Verdeso excipients?

1. Generic aerosol foam

This is the largest near-term opportunity. A generic sponsor can compete on:

• Lower wholesale acquisition cost.
• Pharmacy substitution.
• Medicaid and managed-care formulary access.
• Reliable canister yield.
• Comparable foam quality.
• Pediatric labeling alignment.

The main risk is commoditization. Multiple manufacturers can pursue the same reference-product architecture, making supply reliability and contracting more important than excipient novelty.

2. Authorized generic or regional licensing

The NDA holder or a marketing partner could commercialize an authorized generic through a contract manufacturer. This can protect channel share while allowing lower-price access without immediately ceding the entire market to independent ANDA sponsors.

Potential licensing partners include:

• Dermatology-focused specialty pharmaceutical companies.
• Generic manufacturers with aerosol-filling capacity.
• Contract development and manufacturing organizations with topical-foam expertise.
• Regional firms seeking pediatric dermatology products.

The most valuable licensing asset would be a validated foam platform with established container, valve and stability data, not merely the desonide API.

3. Preservative-free pediatric foam

A preservative-free or lower-preservative formulation could command a premium if it demonstrates improved tolerability and maintains microbial protection through packaging and manufacturing controls.

Commercial positioning would focus on:

• Infants and young children.
• Patients with sensitive or barrier-damaged skin.
• Patients who report burning or irritation from conventional vehicles.
• Caregivers seeking low-residue application.

The product would need evidence that improved excipient tolerability does not compromise delivered dose, stability or microbiological quality.

4. Non-aerosol delivery

A mechanically generated foam or bag-on-valve system could address concerns associated with flammable hydrocarbon propellants. The opportunity is strongest in markets with transportation, storage or sustainability pressure related to aerosol products.

The risks include:

• Higher unit packaging cost.
• Different patient-use technique.
• Device reliability requirements.
• Potentially different spray or foam performance.
• Need to establish comparability with the reference product.

5. Combination dermatology products

Desonide foam could be combined with barrier-supportive excipients or positioned alongside moisturizers, cleansers and anti-inflammatory maintenance products. A fixed-dose combination would face a higher regulatory threshold, but a coordinated product portfolio could increase patient retention without changing the approved drug product.

Potential adjacent categories include:

• Ceramide-containing moisturizers.
• Colloidal oatmeal products.
• Low-irritancy cleansers.
• Fragrance-free pediatric skin-care products.
• Maintenance regimens that reduce repeated corticosteroid exposure.

How does Verdeso compare with competing topical corticosteroid vehicles?

Vehicle	Strengths	Weaknesses	Commercial position
Foam	Fast spreading, low residue, useful on hair-bearing skin	Aerosol cost, flammability, packaging complexity	Premium convenience
Cream	Familiar, broadly accepted, lower packaging complexity	May feel less cosmetically elegant	Mainstream generic competition
Ointment	Strong occlusion and barrier effect	Greasy, difficult to apply over hair	High-efficacy vehicle for dry lesions
Lotion	Easy coverage over larger areas	Can sting and may provide less occlusion	Broad-area use
Gel	Low residue and rapid drying	Alcohol or solvent irritation risk	Niche cosmetic preference
Solution or spray	Easy distribution over hair-bearing areas	Drying and irritation concerns	Targeted niche use

Verdeso’s competitive advantage is vehicle-based. Desonide itself is not highly differentiated from other low-potency topical corticosteroids. The foam format may support adherence where patients avoid ointments or creams because of greasiness.

What generic launch scenarios exist for Verdeso?

Scenario 1: Low-price generic foam

A manufacturer launches a close formulation after satisfying ANDA requirements. Pricing is aggressive, and market share is driven by substitution and payer contracts. This is the most likely competitive model if no enforceable patent barrier remains.

Scenario 2: Premium differentiated foam

A company launches a product with improved skin feel, reduced irritation or a preservative-free design. The product avoids direct price competition but requires evidence and physician education.

Scenario 3: Authorized generic

The incumbent or its partner supplies a lower-priced version. This may reduce the incentive for independent generic entrants and preserve manufacturing scale.

Scenario 4: Device-led reformulation

A sponsor uses bag-on-valve or mechanical foam technology. The product can pursue a higher price but faces additional device and human-factors requirements.

What geographic opportunities exist for Verdeso-related products?

The U.S. market offers the clearest ANDA pathway because Verdeso has an FDA-approved reference product and an established topical corticosteroid category.[1,2]

International opportunities depend on local approval requirements, reference-product recognition, trademark ownership and national patent status. A sponsor should expect differences in:

• Approved pediatric age ranges.
• Desonide concentration and labeling.
• Acceptable preservatives.
• Propellant restrictions.
• Aerosol transport requirements.
• Stability-zone testing.
• Prescription classification.
• Reimbursement for topical dermatology products.

A non-aerosol package may have greater appeal in markets where hydrocarbon propellants face environmental, transportation or pharmacy-storage constraints.

How strong is the commercial patent estate for Verdeso?

The product’s commercial defensibility is likely to depend on the combination of regulatory position, formulation know-how, manufacturing capability and any currently listed or enforceable patents. Desonide has long generic availability in other topical forms, which limits molecule-level protection.

A strong competitive position would require at least one of the following:

• Active formulation or delivery patents.
• Regulatory exclusivity.
• Difficult-to-reproduce foam performance.
• Specialized aerosol manufacturing capacity.
• Strong pediatric or dermatology distribution.
• Payer or pharmacy-channel contracts.
• A differentiated excipient profile supported by clinical tolerability data.

Absent those barriers, a standard desonide foam is vulnerable to price erosion after credible ANDA entry.

Key Takeaways

• Verdeso is desonide 0.05% topical foam for mild to moderate atopic dermatitis.
• Its main value is the foam vehicle, not molecular novelty.
• The core excipient system combines fatty alcohols, surfactant, humectant, preservative, buffer, water and isobutane propellant.
• The lowest-risk generic strategy is a close formulation and aerosol package.
• The strongest differentiated opportunity is a pediatric-friendly, low-irritancy or preservative-free foam.
• A mechanical or bag-on-valve foam could reduce propellant-related constraints but would increase development and packaging complexity.
• Verdeso has no biosimilar risk because desonide is a small molecule.
• ANDA applicants must assess current Orange Book listings and Paragraph IV exposure before launch planning.
• Commercial success will depend on foam performance, pediatric tolerability, manufacturing scale and payer access.
• A standard generic is likely to face rapid price competition unless formulation, device or channel barriers remain enforceable.

FAQs

Is Verdeso a steroid or a biologic?

Verdeso is a topical corticosteroid containing desonide. It is a small-molecule drug and is not a biologic.

Which excipient in Verdeso provides the propellant?

Isobutane is the listed aerosol propellant in the Verdeso formulation.[1]

Can a generic Verdeso use different inactive ingredients?

Potentially. An ANDA applicant must demonstrate that the proposed product meets applicable pharmaceutical-equivalence, performance, stability and bioequivalence requirements. A major change in vehicle or delivery system may require a different regulatory pathway.

Why are cetyl alcohol and stearyl alcohol used in topical foam?

They provide emolliency, consistency and structural support for the foam vehicle. Their ratio can affect residue, collapse behavior, spreadability and drug release.

Does Verdeso have biosimilar competition?

No. Biosimilar competition applies to biological products. Verdeso contains desonide, a small molecule, so relevant competition is from generic topical products and reformulations.

References

1. U.S. Food and Drug Administration. (n.d.). Verdeso (desonide) foam prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: ANDA process and requirements. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.